BioXcel’s OnkosXcel Therapeutics Files for Proposed IPO

This post was originally published on this site

https://i-invdn-com.investing.com/news/LYNXNPEB9M0BY_M.jpg

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Contact Information

CorporateBioXcel TherapeuticsErik Kopp1.203.494.7062ekopp@bioxceltherapeutics.com

Investor RelationsBioXcel TherapeuticsBrennan Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com

Media Russo Partners David Schull or Scott Stachowiak 1.858.717.2310 David.schull@russopartnersllc.com Scott.stachowiak@russopartnersllc.com

Source: OnkosXcel Therapeutics, LLC

Primary Logo

Source: BioXcel Therapeutics